Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis WidensCANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting with the U.S. Food and Drug Administration (FDA), cementing its plans to finalize the Biologics License Application (BLA) for ReNu, its
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures-- Select findings demonstrate that the use of EXPAREL® (bupivacaine liposome injectable suspension) in outpatient Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA) is associated with lower total healthcare costs over various follow-up periods —
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting-- Studies highlight reduced total cost of care and select healthcare resource utilization outcomes in total knee arthroplasty (TKA) and spinal fusion --
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation-- Issues Statement in Response to DOMA’s Nomination of Director Candidates --
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on March 3, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare ConferenceBRISBANE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the Barclays 28th Annual Global Healthcare Conference at 2:30 PM ET on Wednesday, March 11, 2026 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)-- Studies highlight the clinical effectiveness of EXPAREL for total knee arthroplasty and long-term pain management with ioveraº for patients with osteoarthritis (OA) of the knee --
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results— Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years —
Pacira to Report 2025 Financial Results on Thursday February 26, 2026BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2025 financial results after the close of the U.S. markets on Thursday February 26, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET.
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid ChoicesBRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted new survey findings released by the Voices for Non-Opioid Choices (Voices) coalition following the first year of the Non-Opioids Prevent Addiction (“NOPAIN”) Act.
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on February 3, 2026 to 14 new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise --
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years--
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare ConferencesBRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will present at the 44th Annual J.P. Morgan Healthcare Conference at 11:15 AM PST (2:15 PM EST) on Wednesday, January 14, 2026. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment----PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries--
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on December 1, 2025 to two new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° ---- Fewer iovera° patients required additional spine injections after 180 days ---- No treatment-related adverse events were reported --
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare ConferencesBRISBANE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:
